Cargando…
HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection
BACKGROUND: Statins effectively lower blood cholesterol and the risk of cardiovascular death. Immunomodulatory actions, independent of their lipid-lowering effect, have also been ascribed to these compounds. Since macrophages participate in several vascular pathologies, we examined the effect of sta...
Autores principales: | Vamvakopoulos, Joannis E, Green, Colin |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC183828/ https://www.ncbi.nlm.nih.gov/pubmed/12871602 http://dx.doi.org/10.1186/1471-2261-3-6 |
Ejemplares similares
-
Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
por: Würtz, Peter, et al.
Publicado: (2016) -
Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor
por: Bose, Sucharita, et al.
Publicado: (2023) -
Predictive Modeling
of HMG-CoA Reductase Inhibitory
Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023) -
HMG CoA reductase inhibitors (statins) to treat Epstein–Barr virus-driven lymphoma
por: Cohen, J I
Publicado: (2005) -
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
por: Palmer, Suetonia C., et al.
Publicado: (2015)